Anna‐Maria Fink

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo et al. · New England Journal of Medicine · 2019 · 852 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Barbara Eichhorst, Anna‐Maria Fink, Jasmin Bahlo et al. · The Lancet Oncology · 2016 · 622 citations

Medicine, Immunology, Oncology +14

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Kirsten Fischer, Paula Cramer, Raymonde Busch et al. · Journal of Clinical Oncology · 2012 · 431 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Barbara Eichhorst, Raymonde Busch, Stephan Stilgenbauer et al. · Blood · 2009 · 333 citations

Medicine, Oncology, Pharmacotherapy +7

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Othman Al‐Sawaf, Can Zhang, Maneesh Tandon et al. · The Lancet Oncology · 2020 · 327 citations

Medicine, Hematology, Immunology +15